ERBB2 and breast carcinoma: There are many ongoing trials that test the association of CDK4/6 inhibitors to trastuzumab, associated or not with ET in breast cancer HER-2+ (monarcHER, PATRICIA, CLEE011XUS20T, NCI-2016-00626, STU 042013-042).